NCT00005604View on ClinicalTrials.gov

Interleukin-12 Plus Interleukin-2 in Treating Patients With Advanced Solid Tumors

PHASE1CompletedINTERVENTIONAL
Enrollment

25

Participants

Timeline

Start Date

March 31, 2000

Primary Completion Date

July 31, 2003

Conditions
Unspecified Adult Solid Tumor, Protocol Specific
Interventions
BIOLOGICAL

recombinant interleukin-12

Given IV

BIOLOGICAL

aldesleukin

Given SC

OTHER

laboratory biomarker analysis

Correlative studies

Trial Locations (1)

02215

Beth Israel Deaconess Medical Center, Boston

All Listed Sponsors
lead

National Cancer Institute (NCI)

NIH

NCT00005604 - Interleukin-12 Plus Interleukin-2 in Treating Patients With Advanced Solid Tumors | Biotech Hunter | Biotech Hunter